Verona Pharma (VRNA) reported a Q4 loss Thursday of $0.05 per diluted share, compared with a loss of $0.02 a year earlier.
Analysts polled by FactSet expected a loss of $0.19.
Revenue for the quarter ended Dec. 31 was $36.7 million. The company did not report any revenue in the year-ago quarter.
Analysts surveyed by FactSet expected $33 million.
As of Dec. 31, the biopharmaceutical firm reported $399.8 million in cash and cash equivalents.
Shares of the company rose nearly 4% in recent premarket activity.
Price: 66.00, Change: +2.48, Percent Change: +3.90
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。